Cabozantinib ( DrugBank: Cabozantinib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
34. Neurofibromatosis
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02101736 (ClinicalTrials.gov) | June 2014 | 14/3/2014 | Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults | A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults | NF1;Neurofibromatosis;Plexiform Neurofibromas | Drug: Cabozantinib | University of Alabama at Birmingham | NULL | Active, not recruiting | 3 Years | N/A | All | 45 | Phase 2 | United States |